Product Description
The Fungal Microbiota Panel is an in-vitro multiplex real-time polymerase chain reaction (RT-PCR) assay for the qualitative identification of nucleic acids from fungi and bacteria. This method is highly accurate, analytically sensitive, and is used to identify organisms by amplifying and detecting genetic material of pathogens in samples. The panel will aid in the research of causative agents of fungal infections and their prevalence.
The target organisms included in the panel are as follows: Alternaria spp., Aspergilus spp., Epidermophyton floccosum, Scytalidium dimidiatum, Fusarium spp., Curvularia spp., Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis, Cryptococcus spp., Trichosporon spp., Malessezia spp., Trichophyton anthrophilic spp.(targets include: T. rubrum, T. violaceum, T. soudanense, & other species) Trichophyton zoophilic spp. (targets include: T. mentagrophytes, T. interdigitale, T. tonsurans, T. verrucosum, T. simii, T. benhamiae, T. equinum, & other species), Meyerozyma guilliermondii, Microscporum canis, Sarocladium strictum. The panel also includes bacterial add on Pseudomonas aeruginosa and the antibiotic resistance marker, mecA.
Usage Information
Reagent Storage and Use Guidelines | |
|
|
The Following is Included in the Kit | |
|
|
The Following is Supplied by the User: Materials |
|
|
|
Equipment | |
|
|
Instrumentation | |
CFX384 Touch Real-Time PCR Detection System |
Download Product Information Fungal Panel
Limitations of Use
This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §
360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.